CWIAX
Price
$82.59
Change
+$0.54 (+0.66%)
Updated
Jun 2 closing price
Net Assets
151.89B
JORNX
Price
$21.34
Change
+$0.14 (+0.66%)
Updated
Jun 2 closing price
Net Assets
3.25B
Interact to see
Advertisement

CWIAX vs JORNX

Header iconCWIAX vs JORNX Comparison
Open Charts CWIAX vs JORNXBanner chart's image
CWIAX vs JORNX Comparison Chart in %
View a ticker or compare two or three
VS
CWIAX vs. JORNX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CWIAX is a Buy and JORNX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CWIAX has more cash in the bank: 152B vs. JORNX (3.25B). CWIAX pays higher dividends than JORNX: CWIAX (1.33) vs JORNX (0.38). CWIAX was incepted earlier than JORNX: CWIAX (24 years) vs JORNX (26 years). JORNX (0.93) is less costly to investors than CWIAX (0.75). JORNX is a more actively managed with annual turnover of: 48.00 vs. CWIAX (44.00). CWIAX has a lower initial minimum investment than JORNX: CWIAX (250) vs JORNX (2500). CWIAX annual gain was more profitable for investors over the last year : 22.44 vs. JORNX (11.78). CWIAX return over 5 years is better than : 38.19 vs. JORNX (11.78).
CWIAXJORNXCWIAX / JORNX
Total Expense Ratio0.750.9381%
Annual Report Gross Expense Ratio0.750.9381%
Fund Existence24 years26 years-
Gain YTD15.6529.943157%
Front Load4%N/A-
Min. Initial Investment250250010%
Min. Initial Investment IRAN/AN/A-
Net Assets152B3.25B4,674%
Annual Yield % from dividends1.330.38347%
Returns for 1 year22.4411.78190%
Returns for 3 years54.6531.71172%
Returns for 5 years38.1911.78324%
Returns for 10 years122.6385.06144%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSHAX12.600.20
+1.61%
NYLI Cushing® MLP Premier Class A
JCPRX25.76N/A
N/A
JPMorgan US Large Cap Core Plus R5
OIEIX26.19N/A
N/A
JPMorgan Equity Income A
RYBOX65.18N/A
N/A
Rydex Biotechnology A
PSKCX23.33N/A
N/A
Virtus KAR Mid-Cap Growth C